News

Organizations that want to achieve deal success should try to focus on three areas: planning, organizational change, and target management.

Payers and providers must consider the key differences between two consolidation models: "horizontal consolidations" and "vertical consolidations." Here's why.

AHIP presentation: What should payers and providers be doing with all of the data they are collecting?

The FDA has granted Priority Review for ticagrelor (Brilinta, AstraZeneca) for patients with a history of heart attack.

In this blog post, David Calabrese RPh, MHP and Andrea Marks, MS discuss Catamaran's research on opioid abuse. Catamaran is concerned about opioid misuse and is moving forward with plans to combat opioid abuse.

In patients with advanced squamous cell carcinoma (SCC), afatinib significantly improved overall survival (OS) compared to erlotinib, according to data presented at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Waivers offer states an opportunity to expand programs beyond traditional services, giving them greater flexibility and innovation in care delivery and payment models.

The Patient-Centered Outcomes Research Institute (PCORI) recently awarded more than $2 million to the University of Pennsylvania for research on opioid addiction treatment and relapsing in the Philadelphia Prison System. The study assesses the effectiveness of naltrexone to prevent relapse.

FDA approvals for the first week of June 2015.

Mobile health (mhealth) has many benefits for patient care, but lack of oversight and regulatory concerns could raise problems.

Managed healthcare executives can set the table for future economic expansion of interoperability capabilities by following a few simple, straightforward tips.

The National Association of Insurance Commissioners recently released “guidance” on cybersecurity. Here's what healthcare executives should know.

Lymphangioleiomyomatosis (LAM) is a rare, progressive lung disease that primarily affects women of childbearing age. The FDA has approved sirolimus (Rapamune, Pfizer) as the first drug to treat LAM. Rapamune was originally approved to prevent organ rejection.

FDA approved once-daily tiotropium bromide and olodaterol (Stiolto Respimat, Boehringer Ingelheim) Inhalation Spray as a long-term, once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.

Sarilumab may be an effective option for patients with moderately-to-severely active rheumatoid arthritis (RA) according to topline results from a new study.

Because lung function can be substantially reduced by the time most chronic obstructive pulmonary disease (COPD) patients first see a physician, maintenance treatment should be considered at the time of diagnosis, according to new data analyses presented at the American Thoracic Society (ATS) 2015 International Conference.

The Centers for Medicare and Medicaid Services recently instituted a billing code that finally reimburses providers separately for non-face-to-face services.

Rather than reducing unnecessary, preventable emergency department visits, some healthcare experts say the Affordable Care Act has actually caused them to increase.

Insurers have raised concerns about the regulation and approval process of medical devices in the wake of a recent advisory notice issued by the FDA on the risks of laparoscopic power morcellators.

More than 750 government and private ACOs are now in place, helping healthcare transition away from fee-for-service. Find out what's working and what's planned for the future.

As the number of people with diabetes in the U.S. continues to climb, plans and integrated health systems are employing personalized strategies to help manage the disease.

Critics charge that the practice of adverse tiering to deter costly patients is violating the Affordable Care Act's coverage mandate.

In patients with moderate-to-severe chronic obstructive pulmonary disease (COPD), investigational indacaterol/glycopyrronium (QVA149) bromide significantly improved lung function compared to the single bronchodilators, according to data presented at the American Thoracic Society (ATS) International Conference in Denver, May 15 to 20.

The Centers for Medicare & Medicaid Services (CMS) proposed to modernize Medicaid and Children’s Health Insurance Program (CHIP) managed care regulations to update the programs’ rules and strengthen the delivery of quality care for beneficiaries. This proposed rule is the first major update to Medicaid and CHIP managed care regulations in more than 10 years.

FDA has joined nonprofit National Forum for Heart Disease and Stroke Prevention to advance the cause of a heart-healthy and stroke-free society in a first-of-its-kind cooperative public education program to reduce the burdens of heart disease and stroke.

Because of overuse and misuse, some antibiotics are losing effectiveness against highly resistant bacteria.

The FDA approved Eli Lilly’s Humalog 200 units/mL KwikPen (insulin lispro 200 units/mL; U-200), the company announced on May 27.

Among the many poster sessions being presented at the 2015 American Society of Clinical Oncology (ASCO) annual meeting in Chicago, IL, are several on the latest trials that are planned to evaluate potential treatment options for breast cancer. These trials include 1 phase 2 study and 3 phase 3 studies.

The FDA approved two new treatments to treat irritable bowel syndrome with diarrhea (IBS-D), Viberzi (eluxadoline) and Xifaxan (rifaximin), this week.